Cargando…

Optimizing Safety Surveillance for COVID-19 Vaccines at the National Pharmacovigilance Centre Lareb: One Year of COVID-19 Vaccine Experience

INTRODUCTION: Due to the COVID-19 vaccination campaign, national pharmacovigilance (PV) centres had to deal with high volumes of Individual Case Safety Reports (ICSRs) that needed to be processed and assessed in a short time span. This necessitated the development of a dedicated system to enable nea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Oosterhuis, Ingrid, Scholl, Joep, van Puijenbroek, Eugène, Kant, Agnes, van Hunsel, Florence
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2022
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9645343/ https://www.ncbi.nlm.nih.gov/pubmed/36350465 http://dx.doi.org/10.1007/s40264-022-01253-5

Ejemplares similares

Red yeast rice (Monascus purpureus) supplements: Case series assessment of spontaneously reported cases to The Netherlands Pharmacovigilance Centre Lareb
por: Vrolijk, Misha F., et al.
Publicado: (2020)

Lareb study on COVID-19 vaccine-related menstrual disorders
Publicado: (2022)

Authors’ Reply to Mungmunpuntipantip et al.’s Comment on “Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands”
por: Kant, Agnes, et al.
Publicado: (2022)

Safety Concerns Reported by Patients Identified in a Collaborative Signal Detection Workshop using VigiBase: Results and Reflections from Lareb and Uppsala Monitoring Centre
por: Watson, Sarah, et al.
Publicado: (2017)

Description of Frequencies of Reported Adverse Events Following Immunization Among Four Different COVID-19 Vaccine Brands
por: Kant, Agnes, et al.
Publicado: (2022)

COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomes
por: Rolfes, Leàn, et al.
Publicado: (2022)

A prediction model‐based algorithm for computer‐assisted database screening of adverse drug reactions in the Netherlands
por: Scholl, Joep H.G., et al.
Publicado: (2017)

Time to onset in statistical signal detection revisited: A follow‐up study in long‐term onset adverse drug reactions
por: Scholl, Joep H.G., et al.
Publicado: (2019)

Evaluation of pharmacovigilance systems for reporting medication errors in Africa and the role of patients using a mixed-methods approach
por: Sabblah, George Tsey, et al.
Publicado: (2022)

Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature
por: Duijster, Janneke W., et al.
Publicado: (2023)

Spontaneously reported adverse events following COVID-19 basic and booster immunizations in the Netherlands
por: van der Boor, Saskia C., et al.
Publicado: (2023)

Post-Menopausal Vaginal Hemorrhage Related to the Use of a Hop-Containing Phytotherapeutic Product
por: van Hunsel, Florence, et al.
Publicado: (2015)

The Impact of Experiencing Adverse Drug Reactions on the Patient’s Quality of Life: A Retrospective Cross-Sectional Study in the Netherlands
por: Rolfes, Leàn, et al.
Publicado: (2016)

Myocarditis and pericarditis in association with COVID-19 mRNA-vaccination: cases from a regional pharmacovigilance centre
por: Istampoulouoglou, Ioanna, et al.
Publicado: (2021)

Quantification of Adverse Drug Reactions Related to Drug Switches in The Netherlands
por: Glerum, Pieter J., et al.
Publicado: (2020)

French organization for the pharmacovigilance of COVID-19 vaccines: A major challenge
por: Lacroix, Clémence, et al.
Publicado: (2021)

COVID-19 VACCINES AND ATRIAL FIBRILLATION RISK: A PHARMACOVIGILANCE ANALYSIS
por: Kattubadi, Ayeesha, et al.
Publicado: (2022)

Pharmacovigilance for COVID-19 vaccines: A 1-year experience in France
por: Crommelynck, S., et al.
Publicado: (2022)

A Call to Enhance Active and Transparent Pharmacovigilance for COVID-19 Vaccines
por: Kunene, Khontile Nobuhle, et al.
Publicado: (2023)

Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study
por: de Vries, Sieta T., et al.
Publicado: (2019)

Global safety monitoring of COVID-19 vaccines: how pharmacovigilance rose to the challenge
por: Rudolph, Annette, et al.
Publicado: (2022)

COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study
por: Ferrara, Francesco, et al.
Publicado: (2022)

Anaphylactic Reactions to COVID-19 Vaccines: An Updated Assessment Based on Pharmacovigilance Data
por: Boufidou, Fotini, et al.
Publicado: (2023)

Pharmacovigilance in vaccines
por: Budhiraja, Salil, et al.
Publicado: (2010)

2389. Surveillance evaluation of COVID-19 pharmacovigilance—Karakalpakstan, Uzbekistan, 2022
por: Tursinov, Yunis, et al.
Publicado: (2023)

The Quality of Clinical Information in Adverse Drug Reaction Reports by Patients and Healthcare Professionals: A Retrospective Comparative Analysis
por: Rolfes, Leàn, et al.
Publicado: (2017)

Factors Contributing to Best Practices for Patient Involvement in Pharmacovigilance in Europe: A Stakeholder Analysis
por: van Hoof, Monica, et al.
Publicado: (2022)

Does patient reporting lead to earlier detection of drug safety signals? A retrospective comparison of time to reporting between patients and healthcare professionals in a global database
por: Rolfes, Leàn, et al.
Publicado: (2018)

Motives for reporting adverse drug reactions by patient-reporters in the Netherlands
por: van Hunsel, Florence, et al.
Publicado: (2010)

Adverse events related to COVID-19 vaccines: the need to strengthen pharmacovigilance monitoring systems
por: Shrestha, Sunil, et al.
Publicado: (2021)

Beyond the jab: A need for global coordination of pharmacovigilance for COVID-19 vaccine deployment
por: Naniche, Denise, et al.
Publicado: (2021)

Cluster headache after COVID-19 vaccination with Comirnaty: A signal in pharmacovigilance database()
por: Rochoy, Michaël, et al.
Publicado: (2022)

COVID-19 Vaccines Adverse Reactions Reported to the Pharmacovigilance Unit of Beira Interior in Portugal
por: Amaro, Carina, et al.
Publicado: (2022)

COVID-19 Vaccines and Atrial Fibrillation: Analysis of the Post-Marketing Pharmacovigilance European Database
por: Ruggiero, Rosanna, et al.
Publicado: (2023)

Adverse Drug Reactions of Intranasal Corticosteroids in the Netherlands: An Analysis from the Netherlands Pharmacovigilance Center
por: Rollema, Corine, et al.
Publicado: (2022)

Severe Secondary Polycythemia in a Female-to-Male Transgender Patient While Using Lifelong Hormonal Therapy: A Patient’s Perspective
por: Ederveen, Ellen G. T., et al.
Publicado: (2018)

Guiding axes for drug safety management of pharmacovigilance centres during the COVID-19 era
por: Ferreira-da-Silva, Renato, et al.
Publicado: (2021)

Diabetes patient’s pharmacovigilance knowledge and risk perception: the influence of being part of a patient organisation
por: Matos, Cristiano, et al.
Publicado: (2020)

Safety surveillance and challenges in accelerated COVID-19 vaccine development
por: Cole, Abimbola, et al.
Publicado: (2022)

Aide-soignante en centre de vaccination contre la Covid-19
por: Di Martino, Florence, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_eal9ojq6v26alrutcdqgk7moi4